ERBB2 and breast carcinoma: Marianne et al reported 1 000 high‐risk breast cancer patients received postmastectomy radiotherapy (PMRT) and demonstrated that HoR, HER2 status, and the constructed subtypes may be predictive of locoregional recurrence and survival.